Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Austrian breast cancer screening a success:

This article was originally published in Clinica

Executive Summary

The steady fall in the number of women dying from breast cancer in Austria over the past 10 years is a result of effective early detection and improved therapy, says the Vienna regional sickness fund (WGKK). Vienna introduced screening of women between the ages of 50-70 under the auspices of the WGKK, the Viennese doctors' chamber and the Vienna council, in 2001. The screening added to earlier measures that saw the three-year survival rate, which was some 15% in the 1970s, reach 61% by the end of the 1990's, it claims. The five-year rate has also risen from 10-40% over the same period. 18 Viennese women contract breast cancer and eight die from the disease per week, on average.

You may also be interested in...



Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention

Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.

US FDA Offers More Advice On Mid-Trial Changes For Pandemic-Impacted Studies

A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.

US Filing Eyed After Qurient's Novel TB Candidate Proves Mettle

South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.

Topics

UsernamePublicRestriction

Register

MT067496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel